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HESl News sponsors a series of "Guest Ptlspectives" in each 
edition as a means of introducing some of the individuals who 
devote so much of their time, energy, and talent to the goals and 
objectives of HESI. We thank Dr. Robert L. Brent, Distinguished 
Professor of Pediatrics, Radiology and Pathology, Thomas 
Jefferson Universib, A.1. duPont Hospital for Children, for 
taking the time to introduce us to his background and interests, 
and share some of his impressions of HESI. 
I first met Alex Malaspina in 
1984 when he and Dr. Jack Filer 
came to Philadelphia to discuss 
the possible creation of a new 
organization that would be part 
of ILSI. Earlier, we had spoken on 
the telephone at length about this 
new organization. I was looking 
forward to our meeting because 
of the expected focus of the new 
organization on the reproductive 
and developmental risks caused 
by environmental exposures. I 
knew Jack Filer very well. He was 
a pediatrician who graduated 
from the ~niversitfof Rochester 
Medical School (my alma mater 
as well). His research, teaching, 
and administrative activities were 
in the field of nutrition. Jack had 
recommended me to Alex. We met 
on two other occasions at the Stein 
Research Center, the developmen- 
tal and radiation biology institute 
that I directed. After these 
meetings, we agreed that the new 
organization would be devoted to 
the entire field of environmental 
toxicology, and Alex named the 
new organization the Health 
and Environmental Science 
Institute. The structure of ILSI 
was used as the framework for 
HESI which meant that the Board 
of Trustees would be tripartite, 
with corporate representatives, 
academic representatives, and 
some governmental representa- 
tion. This was probably the most 
important aspect of HESI, because 
it provided the checks and bal- 
ances that markedly reduced the 
idlegation directed toward similar 
organizations that primarily 
represented the best interests of 
industry. A lengthy conflict of 
interest document evolved that 
was distributed at every meeting 
and was frequently flashed on 
the screen before each scientific 
session. Each board member knew 
that there were certain activities 
and interactions (for example, 
political activity or lobbying) that 
were inappropriate for Board 
members of a not-for-profit orga- 
nization. 
At the first meeting of HESI, I met 
all the members of the Board. I 
was impressed. The quality and 
accomplishments of the scientists 
that represented industry and 
academia were outstanding. The 
annual scientific meetings were 
worth attending because they 
were in the forefront of scientific 
advances. I personally did not miss 
a single scientific session, and I 
certainly did not miss the opening 
reception and in the early days, 
the final sit down banquet. 
As HESI matured, so did the 
administrative structure of 
the organization. The usual 
organizational committees were 
in place from the start: 1) Bylaws 
and Rules Committee, 2) Scientific 
Program Committee, 3) Nominat- 
ing Committee for selecting officer 
candidates and board members, 
4) meeting site selection, and 
5) Finance Committee. As the 
organization matured, the goals 
were refined and new committees 
were formed to attain the goals 
that crystalized in the minds of 
the officers and members: 
6) Membership Development 
Committee, 7) Program Strategy 
and Stewardship Committee, 
8) technical project committees, 
and 9) Emerging Issues Steering 
Committee. 
These latter three committees 
were important in that they 
encouraged the submission of 
new projects that were periodi- 
cally re-evaluated as to whether 
they were accomplishing their 
goals and whether their work was 
complete. Peer review was an es- 
sential feature for all publications, 
both in-house and by outside 
reviewers. New board members 
may be under the impression that 
the present structure of HESI was 
in place from the beginning of 
the organization. That impression 
could not be further from-the 
truth. 
One of the most important 
events in HESI's history was the 
selection of Dr. Michael Holsapple 
as HESI's leader in 2002. He 
applied his leadership skills and 
his limitless source of energy to 
the HESI organization, and it has 
worked magic on the enthusiasm 
of the staff and board members. 
We were all excited by our leader's 
election as the vice-president of 
the SOT. This honor is a feather 
in Michael's cap and an important 
indication of HESI's increasing 
recognition as a respected and 
credible organization. 
Most of the members of HESI are 
ready and willing to work, write, 
and function on committees. 
Like every volunteer organiza- 
tion, we have a few individuals 
who are difficult to motivate; 
however, most of the members are 
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enthusiastic about meeting their responsibilities and the 
goals of the organization. The recent Mapping exercise 
initiated by Dr. Lewis Smith consumed over three years 
of staff and scientists' time. The manuscript describing 
this exercise is complete and was accepted for publication 
in Critical Reviews in Toxicology. I believe it will be an 
important HESI publication that will put HESI on the 
map (pun intended). 
I remember that when I was elected for a three-year term 
to the Board, the rules were that you could be re-elected, 
but that was not a guarantee. As the years went by, I 
noticed that many of the colleagues who were elected 
with me in the early years were gone, and this happened 
again and again. I said to my wife, "I wonder if they 
have forgotten about me?" I believe I was elected five 
times, and I am most appreciative of the opportunities 
and education in toxicology that I received from HESI's 
activities. It has been a wonderful experience and I will 
continue to wish HESI future successes and important 
accomplishments. It is a very important international 
organization, and of which the membership should be 
very proud. 
HESI Committee to Submit 
a Biomarker Qualification 
Package to FDA 
The Nephrotoxicity Working Group of the 
HESI Biomarkers Technical Committee will 
submit a voluntary biomarker qualification 
data package (VXDS) to the FDA at the end of 
April 2008. The focus of the submission will 
be the analytical and biological validation 
study data generated by the working group 
over the last three years on the markers RPA- 
1, clusterin, and alpha- and mu-GST. These 
data will be evaluated by FDA reviewers to 
assess their utility for specific preclinical safety 
applications. 
For more information, contact Syril D. Pettit, 
MEM, Senior Scientific Project Manager, at 
spettit@hesiglobal.org. 
HESI Goes to Tokyo 
On February 20,2008, HESI led a 
well-attended outreach meeting 
at the Tokyo Opera City building 
in Tokyo, Japan. More than 40 
Japan-based scientists from the 
pharmaceutical and chemical 
sectors, academia, and govern- 
ment attended the meeting. The 
session provided an important 
opportunity to bridge geographic 
and time boundaries, and have 
valuable face-to-face discussions 
with our Japanese colleagues. 
Dr. Michael Holsapple (HESI 
Executive Director), Dr. Marc 
Bonnefoi (sanofi-aventis and 
HESI Vice-President), and 
Ms. Syril Pettit (HESI Senior 
Scientific Program Manager) 
represented HESI at the session. 
The one-day program included 
an overview of the HESI orga- 
nization and mission, as well as 
presentations on the biomarkers, 
genomics, nanotechnol- 
ogy, protein allergenicity, and 
Attendees at the February 2008 HESI 
Outreach Meeting in Tokyo, Japan. (Photo 
by S. Pettit) 
in vitro genotoxicity committees. 
Participants were offered op- 
portunities to provide written 
and verbal feedback on challenges 
and benefits of working with the 
HESI organization. The need for 
more frequent HESI activities and 
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a greater HESI presence in Japan 
emerged as strong recommenda- 
tions from the session. 
Drs. Makoto Hiyashi (Japan National 
Institute of Health Sciences), Molsapple, 
and Bonnefoi (left to right) discuss in vitro 
genotoxicity testing paradigms during a 
meeting break. (Photo by S. Pettit) 
HESI looks forward to returning 
to Japan several times in the 
next 18 months with sessions at 
the Japan Society of Toxicology 
meeting, Japan Environmental 
Mutagen Society, and other 
scientific forums. 
Special thanks to sanofi-aventis in 
Tokyo for assisting with logistical 
support for the meeting. 
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